Business, energy, technology, markets and global industry news from Business News Today

AstraZeneca

PharmaDeviceNews AstraZeneca
Representative image: Respiratory medicine deal discussion highlighting Sino Biopharmaceutical’s AstraZeneca TQC3721 licensing agreement and expanded GSK inhaler commercialization rights in China.
Pharma & Biotech

Why Sino Biopharmaceutical’s twin respiratory deals may worry global pharma rivals

Sino Biopharmaceutical Limited has secured two respiratory medicine transactions involving AstraZeneca PLC and GSK plc, strengthening both its out-licensing and China commercialization strategy. Its subsidiary Chia Tai Tianqing Pharmaceutical Group granted AstraZeneca exclusive rights outside China to develop, manufacture and commercialize TQC3721, an investigational PDE3/4 inhibitor for chronic respiratory disease, while separately obtaining mainland China

Read More
Abbisko Therapeutics and AstraZeneca are testing oral PD-L1 inhibitor lumipodlin with Tagrisso in EGFR-mutated non-small cell lung cancer, putting safety, pneumonitis risk and treatment durability under close scrutiny. Representative image.
Pharma & Biotech

AstraZeneca adds Abbisko’s lumipodlin to expanding Tagrisso combination strategy

Discover why Abbisko and AstraZeneca are testing oral PD-L1 inhibitor lumipodlin with Tagrisso in EGFR-mutated lung cancer.

Read More
Representative image: Enhertu’s EU tumor-agnostic approval highlights how HER2 testing and precision oncology diagnostics could shape treatment access for advanced solid tumors.
Medical Devices & Diagnostics

Enhertu wins EU tumor-agnostic approval, but HER2 testing will decide its real impact

The European approval takes Enhertu beyond organ-specific oncology, although its clinical reach will depend on reliable HER2 testing, reimbursement and safety management.

Read More
AstraZeneca and YMCA of the USA are expanding community-based cancer screening education, early detection awareness and survivorship support to help close gaps in cancer care across the United States. Representative image.
Features & Analysis

AstraZeneca and YMCA target the overlooked barriers delaying cancer screening in America

AstraZeneca is funding a five-year YMCA cancer initiative that will begin in 75 communities, but its impact will depend on whether education leads to completed screenings, clinical referrals and sustained survivor support.

Read More
CHMP backs Datroway in first-line TNBC
Pharma & Biotech

Datroway nears EU first-line approval for metastatic triple-negative breast cancer

Discover how Datroway’s EU recommendation could reshape first-line treatment for metastatic triple-negative breast cancer. Read the analysis.

Read More
Pharma & Biotech

AstraZeneca’s Imfinzi gains a first-mover edge in high-risk non-muscle-invasive bladder cancer

Imfinzi has FDA approval with BCG in early high-risk bladder cancer. The next test is adoption, recurrence data and real-world use.

Read More
Representative image: AstraZeneca’s Imfinzi approval with BCG brings immunotherapy into earlier bladder cancer care, reshaping treatment options for high-risk non-muscle-invasive bladder cancer.
Pharma & Biotech

Imfinzi approval gives AstraZeneca a first immunotherapy combination in early bladder cancer

Imfinzi moves into early bladder cancer, but can AstraZeneca turn a DFS win into real-world bladder-preserving impact?

Read More
Representative image: A sterile radiopharmaceutical manufacturing cleanroom with shielded processing equipment and sealed vials, illustrating how Niowave’s Michigan Actinium-225 facility could support the next phase of targeted cancer therapy supply.
Pharma & Biotech

Can Niowave’s Michigan facility ease the Actinium-225 bottleneck in cancer therapy?

Find out how Niowave’s $75m Michigan facility could reshape Actinium-225 supply for targeted cancer therapies.

Read More
Representative image: Enhertu’s EU recommendation could expand HER2 targeted cancer treatment options for patients with previously treated metastatic solid tumors, highlighting the growing role of antibody drug conjugates and precision oncology in advanced cancer care.
Pharma & Biotech

Enhertu nears wider EU approval as HER2 testing moves deeper into solid tumor oncology

Find out how Enhertu’s EU recommendation could reshape HER2 targeted treatment for metastatic solid tumors.

Read More
Representative image: A cancer patient receives infusion-based oncology care in a modern clinic, reflecting Datroway’s FDA approval as a new first-line treatment option for metastatic triple-negative breast cancer patients who are not eligible for immunotherapy.
Pharma & Biotech

AstraZeneca and Daiichi Sankyo deepen ADC ambitions with Datroway’s TNBC approval

Datroway challenges chemotherapy in first-line TNBC. AstraZeneca and Daiichi Sankyo now face the real test: adoption, safety and access.

Read More